Company Overview
Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company dedicated to addressing hereditary and acquired diseases characterized by high unmet medical needs within the United States. The enterprise functions within the Healthcare sector and specifically targets the Biotechnology industry, positioning itself to leverage specialized scientific approaches for therapeutic development. As of the latest data, the company maintains a market capitalization of $417.49M and employs a workforce of 61 individuals to advance its research and development initiatives. Although specific annual revenue figures are not currently disclosed in the available financial statements, the market capitalization of $417.49M suggests that the market values the company's potential pipeline, particularly its gene therapy candidates, significantly above its current operational scale. This valuation indicates that investors are pricing in substantial future commercialization potential rather than current cash flow generation, a common dynamic for clinical-stage entities where product approval and market entry are anticipated to drive future value creation.
Financial Health
The financial statements for Lexeo Therapeutics report a net income of $-104,966,000 and an EBITDA of $-112,933,000, while revenue data is not available for the trailing twelve months. The substantial negative gap between the reported net income and the negative EBITDA reveals a cost structure where interest expenses, taxes, or other non-operating costs are contributing to the overall loss, pushing the net loss higher than the operating loss alone. The company reports a free cash flow of $-68,584,496, indicating that current operations are consuming cash reserves as the firm invests heavily in clinical trials and operational overhead typical of a biotechnology company in the development phase. The company holds $122.76M in cash against $8.46M in debt, resulting in a debt-to-equity ratio of 7.00, which reflects a highly leveraged balance sheet relative to equity but is often standard for capital-intensive biotech firms awaiting product milestones. Despite the high leverage, the current ratio stands at 7.40, which indicates a robust ability to cover short-term liabilities with short-term assets, suggesting strong short-term liquidity management despite the overall negative earnings position. All three margin metrics—Gross Margin, Operating Margin, and Profit Margin—are reported at 0.0%, a figure that reflects the accounting treatment of a company with no recognized revenue yet or significant write-downs that nullify gross profit generation. The Return on Equity is -80.7% and the Return on Assets is -44.7%, metrics that reveal that management is currently destroying shareholder value on a per-dollar basis due to the lack of profitable operations and the dilutionary pressure of negative returns on the asset base.
Valuation Assessment
The company's P/E Ratio (TTM) is listed as N/A due to the absence of earnings, while the Forward P/E is -4.10, a negative figure that implies the market is pricing in future earnings recovery rather than current profitability. The Price to Book ratio is 2.60, indicating that the market is valuing the company at a premium of 2.6 times its book value, which suggests confidence in the intrinsic value of its intellectual property and pipeline assets exceeding its accounting book value. The Price to Sales ratio is N/A and the EV/EBITDA is -2.69, metrics that suggest traditional valuation multiples are not applicable at this stage, with the negative EV/EBITDA highlighting that the enterprise value exceeds earnings by a negative multiple, a standard characteristic for pre-revenue or loss-making biotechnology firms. The stock has traded between a 52-Week Low of $1.45 and a 52-Week High of $10.99, providing a wide trading range that reflects high volatility and significant sentiment swings regarding the company's clinical progress. The Beta is 1.80, which indicates that the stock's price volatility is significantly higher than the broader market, moving 80% more than the market index and reflecting the high risk associated with clinical-stage biotechnology investments.
Growth & Income
Revenue Growth (YoY) and Earnings Growth (YoY) are both listed as N/A, which precludes a direct comparison of earnings growth relative to revenue growth at this time. Since the company is not a dividend payer, the Dividend Yield is N/A and the Payout Ratio is 0.0%, indicating that the company reinvests all available resources, including its cash reserves, into research and development rather than distributing income to shareholders. The absence of a dividend policy aligns with the company's lifecycle stage, where capital allocation is prioritized toward advancing the LX2006 candidate and other pipeline assets through clinical trials rather than generating shareholder income. Consequently, the overall growth and income profile for Lexeo Therapeutics is defined entirely by clinical trial milestones and regulatory approvals rather than current cash flow generation or dividend distributions.